This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Novartis Ag, Novartis Pharma Ag. Active years: 2018-2025.
Location History:
- Fort Worth, TX (US) (2018)
- Summit, NJ (US) (2021)
Company Filing History:
Years Active: 2018-2025
Title: Innovations by Peter Sallstig
Introduction
Peter Sallstig is an accomplished inventor based in Summit, NJ (US). He has made significant contributions to the field of ocular medicine, particularly in the treatment of age-related macular degeneration and other intraocular neovascular disorders. With a total of 3 patents to his name, Sallstig's work has the potential to greatly improve patient outcomes.
Latest Patents
Sallstig's latest patents include innovative methods for treating age-related macular degeneration. One of his notable inventions is a method that reduces the treatment burden for patients suffering from intraocular neovascular disorders. This method involves administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks. Another significant patent focuses on methods for treating ocular diseases with brolucizumab, which also aims to reduce the treatment burden for similar patient populations.
Career Highlights
Throughout his career, Peter Sallstig has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Novartis Pharma AG. His experience in these organizations has allowed him to develop and refine his innovative approaches to ocular treatments.
Collaborations
Sallstig has collaborated with notable professionals in his field, including Werner Schmidt and Andreas Weichselberger. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Peter Sallstig's contributions to ocular medicine through his patents and collaborations highlight his commitment to improving patient care. His innovative methods have the potential to transform treatment protocols for age-related macular degeneration and other ocular diseases.